Skip to main content
Premium Trial:

Request an Annual Quote

Not as Cold

Results are expected soon from a trial of a third RNA-based vaccine that may — if shown to be safe and effective — help meet global vaccine demand, the New York Times reports.

Like the Pfizer-BioNTech and Moderna vaccines that received emergency use authorization from the US Food and Drug Administration, CureVac's candidate vaccine is also mRNA based, the Times notes. But unlike those vaccines, CureVac's does not have to be stored at extremely cold temperatures — it is stable for three months at 41 degrees Fahrenheit (5 degrees Celsius) — making it an appealing option for low-resource regions, it adds.

Because of this, CureVac's candidate vaccine could help meet vaccine demand in middle- and low-income countries, the Times reports. "We still need a lot of vaccine globally," Florian Krammer, a virologist at the Icahn School of Medicine at Mount Sinai, tells it. "I think a lot of people can benefit from it."

The Times adds that results from CureVac's late-stage clinical trial are expected as soon as next week.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.